SCHEMBL26026549

SCHEMBL26026549

O=c1[nH]nc(Oc2c(Cl)cc([N+](=O)[O-])cc2Cl)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARG P13631 1/20 0.46
PARP1 P09874 2/20 0.43
AR P10275 4/20 0.41
LMNA P02545 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CNR2 P34972 1/20 0.37
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
MAPT P10636 2/20 0.37
GUSB P08236 2/20 0.37
POLB P06746 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TNKS O95271 1/20 0.36
NLRP3 Q96P20 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29620356 1.00 RARG (0.46) RARGPARP1ARLMNANPSR1
SCHEMBL26027147 0.87 ALDH1A1 (0.39) RARGPARP1LMNAALDH1A1KMT2A
SCHEMBL26026709 0.87 RARG (0.46) RARGPARP1ARLMNAHTT
SCHEMBL26027642 0.82 TNKS (0.43) RARGLMNAHTTALDH1A1KMT2A
SCHEMBL29578026 0.82 RARG (0.50) RARGPARP1ARLMNANPSR1
SCHEMBL22077248 0.82 RARG (0.50) RARGPARP1ARLMNANPSR1
SCHEMBL29620364 0.80 ALDH1A1 (0.39) HTTALDH1A1KMT2AMEN1HSD17B10
SCHEMBL27089947 0.77 PARP1 (0.45) PARP1ALDH1A1KMT2AMEN1MAPT
SCHEMBL23092338 0.76 PARP1 (0.48) RARGPARP1ARLMNANPSR1
SCHEMBL29578594 0.76 PARP1 (0.48) RARGPARP1ARLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154130-A1 NOVEL THR BETA ANALOGS AND USES THEREOF LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2025-05-15 US disclosed
US-20240051925-A1 METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2024-02-15 US disclosed
WO-2023154842-A1 THR BETA ANALOGS AND USES THEREOF MADRIGAL PHARMACEUTICALS, INC. (US) 2023-08-17 WO disclosed
CN-116406356-A Process for the preparation of 6- (4-nitro-phenoxy) -2H-pyridazin-3-one and 6- (4-amino-phenoxy) -2H-pyridazin-3-one derivatives as intermediates for thyroid hormone analogues 马德里加尔制药公司 2023-07-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051925-A1 METHODS FOR PREPARING PYRIDAZINONE DERIVATIVES CYP7A1, LIPC, CYP11B2 RARG 2094/4885PARP1 4097/4885AR 3517/4885
US-20250154130-A1 NOVEL THR BETA ANALOGS AND USES THEREOF THRB, THRA, TSHR RARG 1139/4885PARP1 4332/4885AR 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.